DK3261644T3 - Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning - Google Patents
Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning Download PDFInfo
- Publication number
- DK3261644T3 DK3261644T3 DK16756477.2T DK16756477T DK3261644T3 DK 3261644 T3 DK3261644 T3 DK 3261644T3 DK 16756477 T DK16756477 T DK 16756477T DK 3261644 T3 DK3261644 T3 DK 3261644T3
- Authority
- DK
- Denmark
- Prior art keywords
- rhinth
- decomposition
- compositions
- treatment
- methods
- Prior art date
Links
- 238000000354 decomposition reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121379P | 2015-02-26 | 2015-02-26 | |
| US201562246455P | 2015-10-26 | 2015-10-26 | |
| US201562247099P | 2015-10-27 | 2015-10-27 | |
| PCT/US2016/019852 WO2016138425A1 (en) | 2015-02-26 | 2016-02-26 | Compositions and methods for treating retinal degradation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3261644T3 true DK3261644T3 (da) | 2021-06-28 |
Family
ID=56789808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16756477.2T DK3261644T3 (da) | 2015-02-26 | 2016-02-26 | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10294220B2 (da) |
| EP (3) | EP3858826A1 (da) |
| JP (1) | JP6691922B2 (da) |
| KR (2) | KR102469789B1 (da) |
| AU (3) | AU2016225037B2 (da) |
| CA (1) | CA2976537C (da) |
| DK (1) | DK3261644T3 (da) |
| ES (2) | ES2879678T3 (da) |
| FI (1) | FI4215527T3 (da) |
| HR (1) | HRP20211050T1 (da) |
| PL (1) | PL3261644T3 (da) |
| PT (2) | PT3261644T (da) |
| WO (1) | WO2016138425A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9326983B2 (en) | 2013-08-01 | 2016-05-03 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
| FR3027804A1 (fr) * | 2014-10-31 | 2016-05-06 | Centre Nat Rech Scient | Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives |
| US11219623B2 (en) | 2015-02-26 | 2022-01-11 | University Of Kentucky Research Foundation | Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis |
| WO2019074884A2 (en) * | 2017-10-10 | 2019-04-18 | University Of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY |
| CN111670032A (zh) | 2018-01-31 | 2020-09-15 | 欧拉泰克治疗有限责任公司 | 预防或治疗阿尔茨海默氏病的方法 |
| US12121530B2 (en) * | 2018-05-11 | 2024-10-22 | Rhode Island Hospital | Composition and methods for treating articulating joint disorders with nucleoside reverse transcriptase inhibitors |
| US20210348164A1 (en) * | 2018-10-09 | 2021-11-11 | University Of Virginia Patent Foundation | Endogenous cytoplasmic alu complementary dna in age-related macular degeneration |
| WO2020154656A1 (en) | 2019-01-25 | 2020-07-30 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| EP4017503A4 (en) * | 2019-08-23 | 2024-03-20 | University of Virginia Patent Foundation | Ddx17 and nlrc4 targeting for inflammatory diseases |
| EP4114409A4 (en) * | 2020-03-20 | 2024-08-07 | University of Virginia Patent Foundation | NRTIS, NRTI METABOLITES AND NRTI ANALOGUES FOR MACULAR DEGENERATION AND VIRAL INFECTIONS |
| US20230257357A1 (en) * | 2020-06-29 | 2023-08-17 | Bacainn Biotherapeutics, Ltd. | Probenecid compounds for the treatment of inflammasome-mediated lung disease |
| WO2023178133A1 (en) | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | Compounds and methods for treating disease |
| WO2024123982A1 (en) * | 2022-12-07 | 2024-06-13 | University Of Virginia Patent Foundation | Inflammasome and vegf inhibition for retinal vascular diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63250396A (ja) * | 1987-04-03 | 1988-10-18 | Taiho Yakuhin Kogyo Kk | ３′−アジド−３′−デオキシチミジン誘導体 |
| ZA886890B (en) | 1987-10-09 | 1989-05-30 | Hoffmann La Roche | Novel dideoxycytidine derivatives |
| EP0355031A3 (de) * | 1988-08-17 | 1990-12-27 | MATTHES, Eckart, Dr. | Substituierte Pyrimidinnucleoside, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
| US6514979B1 (en) | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20100226931A1 (en) * | 2004-06-24 | 2010-09-09 | Nicholas Valiante | Compounds for immunopotentiation |
| US8809517B2 (en) | 2010-06-01 | 2014-08-19 | University Of Kentucky Research Foundation | Method of inhibiting Alu RNA and therapeutic uses thereof |
| CA3205596A1 (en) | 2011-07-18 | 2013-01-24 | University Of Kentucky Research Foundation | Protection of cells from alu-rna-induced degeneration and inhibitors for protecting cells |
| US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| US10562974B2 (en) | 2013-03-13 | 2020-02-18 | University Of Kentucky Research Foundation | Methods of administering IgG1 antibodies and methods of suppressing angiogenesis |
| US9326983B2 (en) * | 2013-08-01 | 2016-05-03 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
-
2016
- 2016-02-26 AU AU2016225037A patent/AU2016225037B2/en active Active
- 2016-02-26 CA CA2976537A patent/CA2976537C/en active Active
- 2016-02-26 KR KR1020217039728A patent/KR102469789B1/ko active Active
- 2016-02-26 WO PCT/US2016/019852 patent/WO2016138425A1/en not_active Ceased
- 2016-02-26 JP JP2017544942A patent/JP6691922B2/ja active Active
- 2016-02-26 EP EP21159854.5A patent/EP3858826A1/en active Pending
- 2016-02-26 ES ES16756477T patent/ES2879678T3/es active Active
- 2016-02-26 PT PT167564772T patent/PT3261644T/pt unknown
- 2016-02-26 PL PL16756477T patent/PL3261644T3/pl unknown
- 2016-02-26 HR HRP20211050TT patent/HRP20211050T1/hr unknown
- 2016-02-26 PT PT231612516T patent/PT4215527T/pt unknown
- 2016-02-26 EP EP23161251.6A patent/EP4215527B1/en active Active
- 2016-02-26 KR KR1020177026078A patent/KR20170123320A/ko not_active Ceased
- 2016-02-26 ES ES23161251T patent/ES3010307T3/es active Active
- 2016-02-26 FI FIEP23161251.6T patent/FI4215527T3/fi active
- 2016-02-26 US US15/552,441 patent/US10294220B2/en active Active
- 2016-02-26 DK DK16756477.2T patent/DK3261644T3/da active
- 2016-02-26 EP EP16756477.2A patent/EP3261644B1/en active Active
-
2021
- 2021-09-16 AU AU2021232790A patent/AU2021232790B2/en active Active
-
2023
- 2023-09-13 AU AU2023229531A patent/AU2023229531B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4215527A1 (en) | 2023-07-26 |
| EP3261644B1 (en) | 2021-06-02 |
| AU2021232790B2 (en) | 2023-10-05 |
| AU2016225037B2 (en) | 2021-06-17 |
| EP3858826A1 (en) | 2021-08-04 |
| EP3261644A1 (en) | 2018-01-03 |
| EP3261644A4 (en) | 2018-07-25 |
| WO2016138425A1 (en) | 2016-09-01 |
| ES3010307T3 (en) | 2025-04-02 |
| FI4215527T3 (fi) | 2024-12-19 |
| AU2021232790A1 (en) | 2021-10-14 |
| AU2023229531A1 (en) | 2023-09-28 |
| KR102469789B1 (ko) | 2022-11-23 |
| US10294220B2 (en) | 2019-05-21 |
| AU2016225037A1 (en) | 2017-09-07 |
| PL3261644T3 (pl) | 2021-10-25 |
| JP6691922B2 (ja) | 2020-05-13 |
| CA2976537C (en) | 2024-05-28 |
| PT4215527T (pt) | 2025-01-07 |
| KR20170123320A (ko) | 2017-11-07 |
| JP2018506558A (ja) | 2018-03-08 |
| HRP20211050T1 (hr) | 2021-11-26 |
| PT3261644T (pt) | 2021-07-07 |
| ES2879678T3 (es) | 2021-11-22 |
| KR20210152580A (ko) | 2021-12-15 |
| US20180044327A1 (en) | 2018-02-15 |
| AU2023229531B2 (en) | 2025-04-10 |
| CA2976537A1 (en) | 2016-09-01 |
| EP4215527B1 (en) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3429596T3 (da) | Cykliske dinukleotide forbindelser og brugs metoder | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3484469T3 (da) | Sammensætninger og fremgangsmåder til potentiering af antimikrober | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3265126T3 (da) | Kombinationsformulering af tesofensin og metoprolol | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer |